Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | TYK2 | P29597 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | TTK | P33981 | 14/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13336071 | 0.89 | MAP4K3 (0.42) | JAK1TYK2JAK3TTKJAK2 | |
| SCHEMBL13336161 | 0.89 | MAP4K3 (0.42) | JAK1TYK2JAK3TTKJAK2 | |
| SCHEMBL13336233 | 0.89 | JAK1 (0.48) | JAK1TYK2JAK3TTKJAK2 | |
| SCHEMBL13336209 | 0.88 | JAK1 (0.45) | JAK1TYK2JAK3TTKJAK2 | |
| SCHEMBL13336204 | 0.87 | JAK1 (0.49) | JAK1TYK2JAK3TTKJAK2 | |
| SCHEMBL13362915 | 0.87 | JAK1 (0.49) | JAK1TYK2JAK3TTKJAK2 | |
| SCHEMBL1570237 | 0.84 | MAP4K1 (0.49) | JAK1TYK2JAK3TTKJAK2 | |
| SCHEMBL1570236 | 0.84 | MAP4K1 (0.49) | JAK1TYK2JAK3TTKJAK2 | |
| SCHEMBL13336269 | 0.82 | JAK1 (0.47) | JAK1TYK2JAK3TTKJAK2 | |
| SCHEMBL13336073 | 0.81 | MAP4K1 (0.38) | JAK1TYK2JAK3TTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | JAK1 1597/4885TYK2 3176/4885JAK3 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.